Equities Analysts Set Expectations for FENC Q3 Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Adherex Technologies to $0.06 from $0.10, while maintaining a Buy rating and a $16 price target. Its full-year 2026 estimate is $0.21 per share.
• Adherex’s latest quarter exceeded expectations, with EPS of $0.05 versus the $0.02 consensus and revenue of $17.87 million versus $16.21 million expected.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and average price target of $17, though insiders recently sold shares and the company continues to report negative net margin and return on equity.

Adherex Technologies Inc. (NASDAQ:FENC - Free Report) - Equities research analysts at HC Wainwright cut their Q3 2026 earnings per share (EPS) estimates for Adherex Technologies in a report released on Wednesday, September 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.06 per share for the quarter, down from their prior forecast of $0.10. HC Wainwright has a "Buy" rating and a $16.00 price target on the stock. The consensus estimate for Adherex Technologies' current full-year earnings is $0.29 per share. HC Wainwright also issued estimates for Adherex Technologies' Q4 2026 earnings at $0.09 EPS, FY2026 earnings at $0.21 EPS, Q1 2027 earnings at $0.13 EPS, Q2 2027 earnings at $0.19 EPS and FY2027 earnings at $0.87 EPS.

Adherex Technologies (NASDAQ:FENC - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.03. The firm had revenue of $17.87 million during the quarter, compared to analysts' expectations of $16.21 million. Adherex Technologies had a negative return on equity of 5.71% and a negative net margin of 6.09%.

A number of other equities research analysts have also recently issued reports on FENC. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adherex Technologies in a research note on Friday, July 17th. B. Riley Financial reissued a "buy" rating and issued a $18.00 price target (up from $16.00) on shares of Adherex Technologies in a research note on Wednesday, August 12th. Zacks Research raised Adherex Technologies from a "strong sell" rating to a "hold" rating in a research note on Monday, May 25th. Wedbush lifted their price objective on Adherex Technologies from $13.00 to $16.00 and gave the stock an "outperform" rating in a report on Wednesday, August 12th. Finally, Wall Street Zen upgraded Adherex Technologies from a "hold" rating to a "strong-buy" rating in a report on Saturday, May 16th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $17.00.

Adherex Technologies Price Performance

Shares of FENC opened at $11.65 on Thursday. Adherex Technologies has a 1 year low of $5.65 and a 1 year high of $13.25. The stock has a 50 day simple moving average of $11.09 and a two-hundred day simple moving average of $9.13. The firm has a market cap of $408.45 million, a P/E ratio of -89.62 and a beta of 1.10.

Insiders Place Their Bets

In related news, insider Pierre Sargis Sayad sold 12,000 shares of Adherex Technologies stock in a transaction on Monday, August 31st. The shares were sold at an average price of $12.18, for a total value of $146,160.00. Following the sale, the insider owned 9,519 shares in the company, valued at $115,941.42. The trade was a 55.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Robert Andrade sold 75,000 shares of the business's stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $11.78, for a total transaction of $883,500.00. Following the transaction, the chief financial officer directly owned 217,675 shares in the company, valued at approximately $2,564,211.50. The trade was a 25.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.73% of the company's stock.

Hedge Funds Weigh In On Adherex Technologies

A hedge fund recently bought a new stake in Adherex Technologies stock. AQR Capital Management LLC acquired a new position in Adherex Technologies Inc. (NASDAQ:FENC - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 10,897 shares of the company's stock, valued at approximately $66,000. Hedge funds and other institutional investors own 55.51% of the company's stock.

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.